- | Heat Biologics
Morrisville firm looking to fight next pandemic
Even as the world battles the coronavirus pandemic, Jeff Wolf, CEO of Morrisville-based Heat Biologics, says his company is studying potential vaccines to limit potential future viral pandemics.
- | Heat Biologics
CDC, Heat Biologics Establish New Pandemic Preparedness Initiatives
North Carolina-based Heat Biologics is also taking a proactive stance against potential pandemic threats. This week, the company established its Biothreat Advisory Board. Heat Chief Executive Officer Jeff Wolf said the board was created to support its biosecurity/biodefense initiative, which was originally conceived as a result of the ongoing pandemic.
- | BeyondSpring Pharmaceuticals
Playing a surprisingly hot hand, BeyondSpring nails a $200M China deal in wake of a pivotal success
BeyondSpring announced this morning a commercialization and co-development agreement between its Chinese subsidiary Wanchunbulin and China’s Jiangsu Hengrui Pharmaceuticals.
- | Check-Cap
Let’s Get to Know Yoav Kimchy, Founder and Chief Technology Officer of Check-Cap
BioSpace recently spoke with Yoav Kimchy, founder and chief technology officer of Check-Cap, a company developing the C-Scan® system to detect precancerous polyps.
- | Windtree Therapeutics
Accelerated Drug Development for Acute Cardiovascular and Pulmonary Care
Windree Therapeutics CEO and President Craig Fraser discusses the unmet needs in acute care, Windtree’s pipeline, the importance of Fast Track designations, and how his past military career primed him for success as a pharma leader.
- | Rain Therapeutics
PharmaShots Interview: Rain Therapeutic’s Avanish Vellanki Shares Insight on the Initiation of P-III MANTRA Trial of Milademetan for Dedifferentiated Liposarcoma
In an interview with PharmaShots, Avanish Vellanki, CEO and Cofounder at Rain Therapeutics shared his views on the initiation of the P-III MANTRA trial to evaluate the safety & efficacy of Milademetan for dedifferentiated liposarcoma and provide updates about the company’s lead candidate, RAIN-32.
- | Revolo Bio
PharmaShots Interview: Revolo’s Jonathan Rigby Shares Insights on the ‘1104 for Eosinophilic Esophagitis
In an interview with PharmaShots, Jonathan Rigby, Group Chief Executive Officer at Revolo Biotherapeutics shared his views on the unique mechanism of ‘1104 and discuss the plan of the company’s clinical studies.
- | Scynexis
